Navigation Links
Sigma Life Science Licenses CompoZr Zinc Finger Nuclease Technology to Horizon Discovery
Date:9/3/2013

ST. LOUIS, Sept. 3, 2013 /PRNewswire/ -- Sigma-Aldrich® Corporation (Nasdaq: SIAL) today announced that Sigma® Life Science, its innovative biological products and services business, has entered a non-exclusive license agreement with Horizon Discovery for use of Sigma's CompoZr® Zinc Finger Nuclease (ZFN) technology. The agreement gives Horizon the commercial freedom to apply the technology alongside its proprietary rAAV technology in its gene-editing service and cell line product business units.

Horizon will immediately begin applying the CompoZr ZFN technology as part of its custom cell line generation service, in which the company currently uses its own rAAV technology, to efficiently and cost-effectively generate a number of novel gene-edited cell lines. The offering will be marketed under Horizon's precision gene-editing brand GENESIS.

"Licensing CompoZr ZFN technology to Horizon is another step in making the most robust and flexible gene editing technology widely available to the entire research community," said Paul Brooks, Ph.D., Global Market Segment Manager at Sigma-Aldrich. "We are pleased that Horizon will be using its expertize to apply both rAAV and CompoZr ZFN gene editing technologies side by side for the benefit of the research community."

"Nuclease based approaches are particularly adept at achieving rapid and efficient knock-out of two or more alleles, making them a perfect complement to Horizon's proprietary rAAV-based precision gene-editing platform," said Eric Rhodes, Chief Technology Officer of Horizon who has 15 years of experience in ZFN and rAAV gene-editing technology. "Our scientists have the expertise and now an unrivalled toolset to help guide customers toward the approach that best answers their biological question and/or suits their timescale and budget."

Under the terms of the deal, Horizon will obtain CompoZr ZFNs manufactured by Sigma Life Science for use in commercial development of cell-based products and to provide commercial gene editing services.
Financial terms were not disclosed.

Cautionary Statement: The foregoing release contains forward-looking statements that can be identified by terminology such as "most robust," "flexible," "efficiently," or similar expressions, or by expressed or implied discussions regarding potential future revenues from products derived there from. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of management regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that these CompoZr ZFNs or related services will assist the Company to achieve any particular levels of revenue in the future. In particular, management's expectations regarding products associated with CompoZr ZFNs or related services could be affected by, among other things, unexpected regulatory actions or delays or government regulation generally; the Company's ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Company's assets and liabilities as recorded in its consolidated balance sheet, and other risks and factors referred to in Sigma-Aldrich's current Form 10-K on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Sigma-Aldrich is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.

About Sigma Life Science: Sigma Life Science is a Sigma-Aldrich business that represents the Company's leadership in innovative biological products and services for the global life science market and offers an array of biologically-rich products and reagents that researchers use in scientific investigation. Product areas include biomolecules, genomics and functional genomics, cells and cell-based assays, transgenics, protein assays, stem cell research, epigenetics and custom services/oligonucleotides. Sigma Life Science also provides an extensive range critical bioessentials like biochemicals, antibiotics, buffers, carbohydrates, enzymes, forensic tools, hematology and histology, nucleotides, amino acids and their derivatives, and cell culture media.

About Sigma-Aldrich:  Sigma-Aldrich, a leading Life Science and High Technology company focused on enhancing human health and safety, manufactures and distributes more than 200,000 chemicals, biochemicals and other essential products to more than 1.4 million customers globally in research and applied labs as well as in industrial and commercial markets. With three distinct business units – Research, Applied and SAFC Commercial – Sigma-Aldrich is committed to enabling science to improve the quality of life. The Company operates in 38 countries, has more than 9,000 employees worldwide and had sales of $2.6 billion in 2012. For more information about Sigma-Aldrich, please visit its website at www.sigma-aldrich.com.

Sigma-Aldrich, Sigma and CompoZr are trademarks of Sigma-Aldrich Co, LLC registered in the US and other countries. GENESIS is a registered trademark of Horizon Discovery Limited.


'/>"/>
SOURCE Sigma-Aldrich Corporation
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. NineSigma Evolves Global Open Innovation through Social Media Platform, NineSights
2. Sigma-Aldrich Corporation Presentations At Three Upcoming Conferences To Be Webcast Live
3. Sigma Life Science and the Culture Collections of Public Health England Collaborate to Distribute Cells and Cellular Extracts
4. Best Practices for Lean Six Sigma in Clinical Development and R&D, New Xtalks Life Sciences Webinar
5. NineSigma Announces Winners in $25,000 Sustainable Packaging Challenge in Conjunction With Scientists Without Borders and Partners
6. Sigma-Aldrich Corporation Declares Increased Quarterly Dividend; Announces Live Webcasts Of Presentations At Two Upcoming Conferences
7. Sigma-Aldrich Corporation Will Hold Its Annual Business Review March 21, 2013
8. Sigma-Aldrich Announces Q4 2012 Earnings Conference Call
9. NineSigma Engages AtriCure in the Ohio Third Frontier Open Innovation Incentive Program
10. Sigma-Aldrich Elects Michael Marberry As Director
11. ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The ... the focus of researchers, engineers, product developers, and industry suppliers gathered last week ... by SPIE, the international society for optics and photonics , the event ...
(Date:4/20/2017)... ... April 20, 2017 , ... As part of the ... challenging patient cases when screening for direct oral anticoagulant. When patients taking direct ... for bridging parental anticoagulation especially for those at high risk of thrombosis recurrence. ...
(Date:4/20/2017)... Maine (PRWEB) , ... April 20, 2017 , ... ... contributions to the scientific and clinical research community’s growing body of knowledge during ... 2017 in the Gracie Theatre and the adjacent Darling Atrium. During the event, ...
(Date:4/20/2017)... ... , ... Parallel6™ , the leader in mClinical™ technologies for improving patient ... one of the 2017 Top 10 eClinical Trial Management Solution Providers by Pharma ... “We take pride in honoring Parallel6 as one of the top 10 companies that ...
Breaking Biology Technology:
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/6/2017)... April 6, 2017 Forecasts by ... Document Readers, by End-Use (Transportation & Logistics, Government & ... Gas & Fossil Generation Facility, Nuclear Power), Industrial, Retail, ... Are you looking for a definitive report ... ...
(Date:4/4/2017)...   EyeLock LLC , a leader of iris-based ... Patent and Trademark Office (USPTO) has issued U.S. Patent ... an iris image with a face image acquired in ... 45 th issued patent. "The ... the multi-modal biometric capabilities that have recently come to ...
Breaking Biology News(10 mins):